-+ 0.00%
-+ 0.00%
-+ 0.00%
Why Agios Pharmaceuticals Bears Were Right Before The Drop
Share
Listen to the news

If you only glanced at Agios Pharmaceuticals’ headlines this year, the story looked upbeat, with EU approval for PYRUKYND in thalassemia and priority FDA review for mitapivat in sickle cell disease. Holding Agios Pharmaceuticals over the past year would have meant a 27.6% loss, including dividends. If you had been weighing an investment a year ago, how could fast improving trial and product news line up with that kind of hit to your capital?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

This theme extends beyond Agios Pharmaceuticals. See which of 36 healthcare AI stocks may still merit a closer look.

The Argument You Would Have Been Weighing On Agios Pharmaceuticals

The shares cost US$42.54 at the start of the period, and investors in Agios Pharmaceuticals were choosing between two very different stories that both sounded plausible.

The bullish narrative pointed to a fair value of US$65 and leaned on rapid expansion of PYRUKYND and mitapivat or tebapivat across four rare blood disorders. Analysts in that camp assumed revenue could rise 124.9% a year over three years.

The bearish view put fair value at US$37.23 and focused on pricing pressure plus reliance on PYRUKYND. That cohort still assumed revenue growth of 76.7% a year but was concerned that any safety issue or slower uptake could hit earnings hard.

NasdaqGS:AGIO 1-Year Stock Price Chart
NasdaqGS:AGIO 1-Year Stock Price Chart

What The Evidence Did To The Agios Pharmaceuticals Thesis

The biggest new fact for Agios Pharmaceuticals was PYRUKYND’s EU approval in adult thalassemia, which backed the bullish focus on broader indications and international reach. RISE UP Phase 3 data in sickle cell disease and EU and U.S. thalassemia launches helped revenue move from US$12.88m in Q3 2025 to US$55.39m in Q3 2026, while the firm still reported a loss of US$65.05m. The period cut both ways.

The key lesson is simple. When a drug story leans on rapid indication and geography expansion, track the mix of new approvals, actual prescriptions and whether rising sales are closing the gap to ongoing losses in quarterly reports.

What You Are Being Asked To Believe About Agios Pharmaceuticals Today

Agios Pharmaceuticals now trades at US$31.59, after the share price fell 27.6% over the past year. The analyst consensus narrative on Simply Wall St views its fair value as above that level, based on a rare hematology platform that could support several future revenue streams.

On that view, a buyer today would need to believe mitapivat centered hematology expansion can scale while spending stays disciplined enough for the business to move closer to breakeven over time.

"Key Takeaways: Analysts expect Agios Pharmaceuticals to build on mitapivat progress and rare hematology launches, with new product approvals and label expansions potentially creating multiple revenue lines that are still in the early stages of being reflected in reported sales. The main requirement for this scenario is successful execution of the rare-disease commercial platform and adjacent indication expansion, including AQVESME thalassemia uptake, potential sickle cell and ITP launches, and disciplined spending supported by a cash balance of about US$1b."

One Narrative disagrees with today's price. → See where this Narrative says Agios Pharmaceuticals should trade

Looking One Step Beyond Agios

Agios Pharmaceuticals is all about targeted blood disorder treatments. That focus raises a natural follow up question.

Patients relying on those therapies still need options for infections, vaccines and broader chronic conditions. That is where a different large drugmaker comes in.

This other group is leaning on a deep late stage pipeline in areas like heart disease, oncology and infectious illness. It is also working on longer acting and more convenient treatment formats.

Those moves aim to keep patients on therapy for longer stretches and across more conditions. If that shift holds, your watchlist for rare disease exposure might sit beside a separate list for broad based drug portfolios.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 26% above its price

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending